{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.84","upperLimit":"6.51","value":"5.49"},{"groupId":"OG001","lowerLimit":"4.60","upperLimit":"6.51","value":"5.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"PD-L1 IC0"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.39","upperLimit":"7.20","value":"5.72"},{"groupId":"OG001","lowerLimit":"5.62","upperLimit":"7.43","value":"5.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"title":"PD-L1 IC1/2/3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"ITT population: all randomized participants, whether or not the assigned study treatment was received","reportingStatus":"POSTED","timeFrame":"From Day 1 up to primary completion date (approximately 26 months)","title":"Progression Free Survival by PD-L1 Status, Intent to Treat Population","type":"SECONDARY","unitOfMeasure":"Months"}